Generic Name and Formulations:
Sulindac 150mg, 200mg; scored tabs.
Various generic manufacturers
Indications for Sulindac:
Rheumatoid arthritis. Osteoarthritis. Ankylosing spondylitis. Acute painful shoulder. Acute gouty arthritis.
Take with food. 150mg twice daily. Acute painful shoulder or gouty arthritis: 200mg twice daily, usually for 7–14 days. All: max 400mg/day.
Aspirin allergy. Coronary artery bypass graft surgery.
Advanced renal disease: not recommended. Active or history of GI bleeding, peptic ulcer, or kidney stones. Heart failure. Impaired renal or hepatic function. Edema. Hypertension. Bleeding disorders. Sepsis. Diabetes. Preexisting asthma. Maintain adequate hydration. Monitor blood, hepatic, renal, and ocular function in chronic use. Discontinue if unexplained fever, pancreatitis, or liver dysfunction occurs. Systemic lupus erythematosus and mixed connective tissue disease. Elderly. Debilitated. Pregnancy (Cat.C); avoid in late pregnancy. Nursing mothers: not recommended.
Increased risk of GI toxicity with aspirin, other NSAIDs, alcohol, smoking. Probenecid increases serum levels. Diflunisal reduces serum levels. Antagonized by, and peripheral neuropathy with, DMSO. Monitor anticoagulants, antihyperglycemics. Caution with methotrexate, cyclosporine, nephrotoxic drugs (increased toxicity). Increased serum lithium levels (monitor). May antagonize diuretics, ACE inhibitors, angiotensin II antagonists (monitor).
NSAID (indene deriv.).
GI ulcer/bleeding/pain, dyspepsia, nausea, diarrhea, constipation, rash (discontinue if occurs), dizziness, headache, tinnitus, edema, nephritis, nephrotic syndrome, pancreatitis, jaundice, hepatitis. See literature re: risk of cardiovascular events.
Formerly known under the brand name Clinoril.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma